Clinical Trial Update: Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe) [Phase 2]

View source ↗

Summary

Phase 2 trial updates for daprodustat (PHI) in anemia of CKD (ASCEND: Fe) have been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• Daprodustat (daprodustat)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Anaemia | Phase 2 | Status: COMPLETED | Results posted: 2023-07-25